Advertisement

Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery

  • Francesco CiconeEmail author
  • Giuseppe Minniti
  • Andrea Romano
  • Annalisa Papa
  • Claudia Scaringi
  • Francesca Tavanti
  • Alessandro Bozzao
  • Riccardo Maurizi Enrici
  • Francesco Scopinaro
Original Article

Abstract

Purpose

We assessed the performance of 6-[18F]-fluoro-l-3,4-dihydroxyphenylalanine (F-DOPA) PET for differentiating radionecrosis (RN) from tumour progression (PD) in a population of patients with brain metastases, treated with stereotactic radiosurgery. The accuracy of F-DOPA PET was compared with that of perfusion-weighted magnetic resonance (perfusion-MR).

Methods

In 42 patients with a total of 50 brain metastases from various primaries F-DOPA PET/CT was performed because of suspected radiological progression at the site of previously irradiated brain metastasis. Several semiquantitative PET parameters were recorded, and their diagnostic accuracy was compared by receiver operating characteristic curve analyses. The diagnosis was established by either surgery or follow-up. A comparison was made between F-DOPA PET and perfusion-MR sequences acquired no more than 3 weeks apart.

Results

Definitive outcome was available in 46 of the 50 lesions (20 PD, 26 RN). Of the 46 lesions, 11 were surgically excised while in the remaining 35 lesions the diagnosis was established by radiological and clinical criteria. The best diagnostic performance was obtained using the semiquantitative PET parameter maximum lesion to maximum background uptake ratio (SUVLmax/Bkgrmax). With a cut-off value of 1.59, a sensitivity of 90 % and a specificity of 92.3 % were achieved in differentiating RN from PD lesions (accuracy 91.3 %). Relative cerebral blood volume (rCBV) derived from perfusion-MR was available for comparison in 37 of the 46 metastases. Overall accuracy of rCBV was lower than that of all semiquantitative PET parameters under study. The best differentiating rCBV cut-off value was 2.14; this yielded a sensitivity of 86.7 % and a specificity of 68.2 % (accuracy 75.6 %).

Conclusion

F-DOPA PET is a highly accurate tool for differentiating RN from PD brain metastases after stereotactic radiosurgery. In this specific setting, F-DOPA PET seems to perform better than perfusion-MR.

Keywords

Brain metastases Stereotactic radiosurgery Brain radionecrosis Amino-acid PET DOPA Perfusion-weighted magnetic resonance 

Notes

Conflicts of interest

None.

References

  1. 1.
    Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003;29:533–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Sneed PK, Suh JH, Goetsch SJ, Sanghavi SN, Chappell R, Buatti JM, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2002;53:519–26.PubMedCrossRefGoogle Scholar
  3. 3.
    Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134–41.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2010;77:996–1001.PubMedCrossRefGoogle Scholar
  7. 7.
    Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011;6:48.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Telera S, Fabi A, Pace A, Vidiri A, Anelli V, Carapella CM, et al. Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. J Neurooncol. 2013;113:313–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Minniti G, D'Angelillo RM, Scaringi C, Trodella LE, Clarke E, Matteucci P, et al. Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol. 2014;117:295–301.PubMedCrossRefGoogle Scholar
  10. 10.
    Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374:1639–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Chao ST, Ahluwalia MS, Barnett GH, Stevens GH, Murphy ES, Stockham AL, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys. 2013;87:449–57.PubMedCrossRefGoogle Scholar
  12. 12.
    Stockham AL, Tievsky AL, Koyfman SA, Reddy CA, Suh JH, Vogelbaum MA, et al. Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery. J Neurooncol. 2012;109:149–58.PubMedCrossRefGoogle Scholar
  13. 13.
    Verma N, Cowperthwaite MC, Burnett MG, Markey MK. Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol. 2013;15:515–34.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Jain R, Narang J, Sundgren PM, Hearshen D, Saksena S, Rock JP, et al. Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging. J Neurooncol. 2010;100:17–29.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoefnagels FW, Lagerwaard FJ, Sanchez E, Haasbeek CJ, Knol DL, Slotman BJ, et al. Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neurol. 2009;256:878–87.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Mitsuya K, Nakasu Y, Horiguchi S, Harada H, Nishimura T, Bando E, et al. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol. 2010;99:81–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Serizawa T, Saeki N, Higuchi Y, Ono J, Matsuda S, Sato M, et al. Diagnostic value of thallium-201 chloride single-photon emission computerized tomography in differentiating tumor recurrence from radiation injury after gamma knife surgery for metastatic brain tumors. J Neurosurg. 2005;102 Suppl:266–71.PubMedCrossRefGoogle Scholar
  18. 18.
    Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96:191–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Belohlávek O, Simonová G, Kantorová I, Novotný Jr J, Liscák R. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? Eur J Nucl Med Mol Imaging. 2003;30:96–100.PubMedCrossRefGoogle Scholar
  20. 20.
    Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol. 2011;103:137–46.PubMedCrossRefGoogle Scholar
  21. 21.
    Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, et al. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med. 2012;53:1367–74.PubMedCrossRefGoogle Scholar
  23. 23.
    Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, et al. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med. 2014;55:30–6.PubMedCrossRefGoogle Scholar
  24. 24.
    McConathy J, Goodman MM. Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev. 2008;27:555–73.PubMedCrossRefGoogle Scholar
  25. 25.
    Langen KJ, Bröer S. Molecular transport mechanisms of radiolabeled amino acids for PET and SPECT. J Nucl Med. 2004;45:1435–6.PubMedGoogle Scholar
  26. 26.
    Yee RE, Cheng DW, Huang SC, Namavari M, Satyamurthy N, Barrio JR. Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA. Biochem Pharmacol. 2001;62:1409–15.PubMedCrossRefGoogle Scholar
  27. 27.
    Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, Pokorny JL, et al. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol. 2013;111:11–8.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Huang SC, Yu DC, Barrio JR, Grafton S, Melega WP, Hoffman JM, et al. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies. J Cereb Blood Flow Metab. 1991;11:898–913.PubMedCrossRefGoogle Scholar
  29. 29.
    Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18F-FDOPA kinetics in brain tumors. J Nucl Med. 2007;48:1651–61.PubMedCrossRefGoogle Scholar
  30. 30.
    Gasparetto EL, Pawlak MA, Patel SH, Huse J, Woo JH, Krejza J, et al. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology. 2009;250:887–96.PubMedCrossRefGoogle Scholar
  31. 31.
    Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. 2008;249:601–13.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Dequesada IM, Quisling RG, Yachnis A, Friedman WA. Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic-pathological study. Neurosurgery. 2008;63:898–903.PubMedCrossRefGoogle Scholar
  33. 33.
    Kano H, Kondziolka D, Lobato-Polo J, Zorro O, Flickinger JC, Lunsford LD. T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery. 2010;66:486–91.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Francesco Cicone
    • 1
    • 2
    Email author
  • Giuseppe Minniti
    • 2
    • 3
  • Andrea Romano
    • 4
    • 5
  • Annalisa Papa
    • 1
    • 2
  • Claudia Scaringi
    • 2
    • 3
  • Francesca Tavanti
    • 4
    • 5
  • Alessandro Bozzao
    • 4
    • 5
  • Riccardo Maurizi Enrici
    • 2
    • 3
  • Francesco Scopinaro
    • 1
    • 2
  1. 1.Unit of Nuclear MedicineSant’Andrea HospitalRomeItaly
  2. 2.Department of Surgical and Medical Sciences and Translational MedicineFaculty of Medicine and Psychology, “Sapienza” University of RomeRomeItaly
  3. 3.Unit of RadiotherapySant’Andrea HospitalRomeItaly
  4. 4.Unit of NeuroradiologySant’Andrea HospitalRomeItaly
  5. 5.Department of Neurosciences, Mental Health and Sensory Organs (Ne.S.M.O.S.), Faculty of Medicine and Psychology“Sapienza” University of RomeRomeItaly

Personalised recommendations